BioSpace News Archive

Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered into a research collaboration with PharmaEssentia Corporation (Taipei Exchange: 6446). The collaboration involves the development of T Cell Receptor (TCR)-T therapy (based on the proprietary TAEST ( T

PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. (U.S. Eastern Time) to discuss its third quarter 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging onto the investors section of PPD’s website at https://investors.ppd.com . An archive copy of the webcast w

Invacare Corporation (Invacare) (NYSE:IVC) announced today the introduction of an innovative and pioneering active patient lift solution for the post-acute care setting into the U.S. market.

Kanaph Therapeutics, a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules, recently completed their Series B funding of 21M USD in South Korea.

Clinical Laserthermia Systems and Otto-von-Guericke-University Magdeburg, Medical faculty are entering into an agreement regarding an Investigator Initiated Trial targeting MRI-Ultrasound, fusion-guided focal laser ablation treatment of prostate cancer, up to Gleason 7a, using CLS’ TRANBERG® Thermal Therapy System for high-precision, minimally invasive interventions.

Final results of IM-UNITI study presented as an oral presentation at United European Gastroenterology Week Virtual 2020 Congress

RhoVac AB announces that the company’s clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002, is expected to be further delayed due to the prevailing Covid-19 pandemic.

HITGEN announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. to acquire Vernalis Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.

Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM”) facility pursuant to its Open Market Sale Agreement SM dated as of September 25, 2020 with Jefferies LLC, as sales agent (the “Sale Agreement”), with participation based on interest